Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus

In a report released on May 10, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report), with a price target of $59.00. The company’s shares closed last Friday at $44.99.

According to TipRanks, Gon Ha is a 2-star analyst with an average return of 0.9% and a 36.29% success rate. Gon Ha covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Soleno Therapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Soleno Therapeutics with a $72.25 average price target, implying a 60.59% upside from current levels. In a report released on May 10, Piper Sandler also reiterated a Buy rating on the stock with a $93.00 price target.

SLNO market cap is currently $1.64B and has a P/E ratio of -16.78.

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SLNO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soleno Therapeutics (SLNO) Company Description:

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.